Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - sapropterin
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpa170adf9726f4d3c42997e5fb725cb61
identifier: http://ema.europa.eu/identifier
/EU/1/21/1620/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Sapropterin Dipharma 100 mg soluble tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-a170adf9726f4d3c42997e5fb725cb61
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/21/1620/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - sapropterin
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Sapropterin Dipharma contains the active substance sapropterin which is a synthetic copy of a body s own substance called tetrahydrobiopterin (BH4). BH4 is required by the body to use an amino acid called phenylalanine in order to build another amino acid called tyrosine.
Sapropterin Dipharma is used to treat hyperphenylalaninaemia (HPA) or phenylketonuria (PKU) in patients of all ages. HPA and PKU are due to abnormally high levels of phenylalanine in the blood which can be harmful. Sapropterin Dipharma reduces these levels in some patients who respond to BH4 and can help increase the amount of phenylalanine that can be included in the diet.
This medicine is also used to treat an inherited disease called BH4 deficiency in patients of all ages, in which the body cannot produce enough BH4. Because of very low BH4 levels phenylalanine is not used properly and its levels rise, resulting in harmful effects. By replacing the BH4 that the body cannot produce, Sapropterin Dipharma reduces the harmful excess of phenylalanine in the blood and increases the dietary tolerance to phenylalanine.
Do not take Sapropterin Dipharma
Warnings and precautions
Talk to your doctor or pharmacist before taking Sapropterin Dipharma, particularly:
You must continue your diet treatment as recommended by your doctor. Do not change your diet without contacting your doctor. Even if you take Sapropterin Dipharma, if your phenylalanine blood levels are not well controlled, you can develop severe neurologic problems. Your doctor should continue to monitor your blood phenylalanine levels often during your treatment with Sapropterin Dipharma, to make sure that your blood phenylalanine levels are not too high or too low.
Other medicines and Sapropterin Dipharma Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. In particular you should tell your doctor if you are using:
Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
If you are pregnant your doctor will tell you how to control phenylalanine levels adequately. If these are not strictly controlled before or when you become pregnant, this could be harmful to you and to your baby. Your doctor will monitor the restriction of dietary phenylalanine intake prior and during pregnancy.
If the strict diet does not adequately reduce phenylalanine amount in your blood your doctor will consider whether you must take this medicine.
You should not take this medicine if you are breast-feeding.
Driving and using machines Sapropterin Dipharma is not expected to affect the ability to drive and use machines.
Sapropterin Dipharma contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .
Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.
Dosing for PKU The recommended starting dose of Sapropterin Dipharma in patients with PKU is 10 mg for each kg of body weight. Take Sapropterin Dipharma as a single daily dose with a meal to increase the absorption, and at the same time each day, preferably in the morning. Your doctor may adjust your dose, usually between 5 and 20 mg for each kg of body weight per day, depending on your condition.
Dosing for BH4 deficiency The recommended starting dose of Sapropterin Dipharma in patients with BH4 deficiency is 2 to 5 mg for each kg of body weight. Take Sapropterin Dipharma with a meal to increase the absorption. Divide the total daily dose into 2 or 3 doses, taken over the day. Your doctor may adjust your dose up to 20 mg for each kg of body weight per day, depending on your condition.
The table below is an example of how an appropriate dose is calculated
Body weight (kg) Number of 100 mg tablets (dose 10 mg/kg) Number of 100 mg tablets (dose 20 mg/kg) 1 2 2 4 3 6 4 8 5 Method of administration For PKU patients, the total daily dose is taken once a day at the same time each day, preferably in the morning.
For BH4 deficiency patients, the total daily dose is divided into 2 or 3 doses over the day.
Use in all patients Place the prescribed number of tablets in a glass or cup of water as accurately described below and stir until dissolved.
It may take a few minutes for the tablets to dissolve. To make the tablets dissolve faster you can crush them. Small particles may be visible in the solution, but they will not affect the effectiveness of the medicine. Drink the dissolved preparation of Sapropterin Dipharma with a meal within 15 to 20 minutes of its preparation.
Use in patients above 20 kg body weight Place the tablets in a glass or cup (120 to 240 ml) of water and stir until dissolved.
Use in children up to 20 kg body weight The dose is based on body weight. This will change as your child grows. Your doctor will tell you:
Your child should drink the solution with a meal.
Give your child the prescribed amount of solution within 15 to 20 minutes after dissolving. If you are not able to give your child s dose within 15 to 20 minutes after dissolving the tablets, you will need to prepare a new solution as the unused solution should not be used beyond 20 minutes.
Supplies needed to prepare and give your child s dose of Sapropterin Dipharma
Ask your doctor for the medicine cup for dissolving the tablets and the 10 ml or 20 ml oral syringe if you do not have these supplies. Steps for preparing and taking your dose:
10 ml.
If you take more Sapropterin Dipharma than you should If you take more Sapropterin Dipharma than prescribed, you may experience side effects that could include headache and dizziness. Immediately contact your doctor or pharmacist if you take more Sapropterin Dipharma than prescribed.
If you forget to take Sapropterin Dipharma Do not take a double dose to make up for a forgotten dose. Take the next dose at the usual time.
If you stop taking Sapropterin Dipharma Do not stop taking Sapropterin Dipharma without prior discussion with your doctor, as phenylalanine levels in your blood may increase.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Few cases of allergic reactions (such as skin rash and serious reactions) have been reported. Their frequency is not known (frequency cannot be estimated from the available data).
If you have red, itchy, raised areas (hives), runny nose, fast or uneven pulse, swelling of your tongue and throat, sneezing, wheezing, serious difficulty in breathing or dizziness, you may be having a serious allergic reaction to the medicine. If you notice these signs, contact your doctor immediately.
Very common side effects (may affect more than 1 in 10 people)
Headache and runny nose.
Common side effects (may affect up to 1 in 10 people) Sore throat, nasal congestion or stuffy nose, cough, diarrhoea, vomiting, stomach ache, too low levels of phenylalanine in blood tests, indigestion and feeling sick (nausea) (see section 2: Warnings and precautions ).
Not known side effects (frequency cannot be estimated from the available data) Gastritis (inflammation of the lining of the stomach), oesophagitis (inflammation of the lining of the gullet).
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle and the carton after EXP . The expiry date refers to the last day of that month.
This medicinal product does not require any special temperature storage conditions. Keep the bottle tightly closed in order to protect from moisture.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Sapropterin Dipharma contains
What Sapropterin Dipharma looks like and contents of the pack Sapropterin Dipharma 100 mg soluble tablets are white to off-white, approximately 10 mm x 3.65 mm, round tablet debossed with 11 on one side and breakline on the other side. The score line is not intended for breaking the tablet.
It is available in bottles with child-resistant closure with screw cap containing desiccant (silica). Packs of 30 and 120 soluble tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Dipharma Arzneimittel GmbH Offheimer Weg 65549 Limburg a. d. Lahn Germany
Manufacturer Depo-Pack S.r.l. Via Giovanni Morandi 21047 Saronno (VA) Italy
or
Pharmadox Healthcare Ltd. KW20A Kordin Industrial Park Paola PLA3Malta
This leaflet was last revised in
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-a170adf9726f4d3c42997e5fb725cb61
Resource Composition:
Generated Narrative: Composition composition-en-a170adf9726f4d3c42997e5fb725cb61
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/21/1620/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - sapropterin
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpa170adf9726f4d3c42997e5fb725cb61
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpa170adf9726f4d3c42997e5fb725cb61
identifier:
http://ema.europa.eu/identifier
/EU/1/21/1620/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Sapropterin Dipharma 100 mg soluble tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en